Office-based buprenorphine treatment for opioid-dependent patients.
about
From research to the real world: buprenorphine in the decade of the Clinical Trials NetworkAcute pain management for patients receiving maintenance methadone or buprenorphine therapy.Integrating buprenorphine treatment into office-based practice: a qualitative studyBuprenorphine tapering schedule and illicit opioid use.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Participant characteristics and buprenorphine dose.Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsDrug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphineInteractions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.Lack of clinically significant drug interactions between nevirapine and buprenorphine.Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsImproving the oral bioavailability of buprenorphine: an in-vivo proof of concept.The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder
P2860
Q33783274-ABD98ECA-D2AA-41E0-87B0-585945121E25Q34485532-48349E5E-9CB0-4924-B7F1-B81E9B0B9B87Q34602077-D866260F-A035-43F5-BD2A-222904D43211Q35147170-D1C1991C-02D3-4E60-AE92-76A3F0C5D556Q35184385-071F2938-791E-4579-9F1A-61F330C5776DQ35738688-6C74E695-AE0E-46F4-BFD1-C3B580C9023AQ35738851-3FB6EC69-9F9D-49F9-AB8D-353F48CE3C9BQ35738878-40957B12-0121-49D1-A7E9-4942DB5A9EF8Q35738885-0E738F60-94C0-4AF8-B18E-12596D2D900FQ35906594-10E7C3AA-8020-4D40-9068-5270AB5A08ACQ36235101-5FBE71F6-A96B-4BBD-9226-001B3A80B771Q36394777-F908D6D2-54DD-4F6A-AAF6-6B2A16B365E0Q37045335-5A9D9B7F-8BFA-4DE5-BB0F-E8152C953B73Q37045349-163E66C0-73D4-4357-8545-905F8093FBF1Q37721776-589FF32D-A7CB-4F37-920E-743EE0A77620Q37763615-CFFC2BAB-8000-47B2-9E28-750827A8D4B7Q38736761-075AF402-6579-47B8-B50D-95AD1ABB8443Q39039330-DAC30EC9-C576-4B92-A815-D1987651EEF3Q44924769-DC2D62C8-DBA8-4D37-825B-6143DDFA501AQ44924772-4019C299-6292-49C8-AA37-BC597F94BECEQ57492671-84262F26-08B4-43AD-8AE1-C1F655336DFC
P2860
Office-based buprenorphine treatment for opioid-dependent patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Office-based buprenorphine treatment for opioid-dependent patients.
@ast
Office-based buprenorphine treatment for opioid-dependent patients.
@en
type
label
Office-based buprenorphine treatment for opioid-dependent patients.
@ast
Office-based buprenorphine treatment for opioid-dependent patients.
@en
prefLabel
Office-based buprenorphine treatment for opioid-dependent patients.
@ast
Office-based buprenorphine treatment for opioid-dependent patients.
@en
P1476
Office-based buprenorphine treatment for opioid-dependent patients.
@en
P2093
Elinore F McCance-Katz
P304
P356
10.1080/10673220490905688
P577
2004-11-01T00:00:00Z